After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...
Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le)Emi-Le has ...
Investor's Business Daily on MSN
Mersana Therapeutics Catapults 200% On Day One Bio's Surprise Buyout
Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it for up to $285 ...
BUFFALO, NY – December 4, 2024 – A new editorial was published in Oncotarget’s Volume 15 on November 22, 2024, entitled “B7-H4: A potential therapeutic target in adenoid cystic carcinoma.” Researchers ...
Investing.com -- Mersana Therapeutics (NASDAQ:MRSN) stock soared 200% following the announcement that Day One Biopharmaceuticals will acquire the company for an upfront payment of $25.00 per share in ...
Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...
Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid ...
Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug ...
The malignancies of Bartholin's gland, although exceedingly rare, represent a diagnostic and therapeutic challenge for clinicians. Bartholin’s gland carcinoma encompasses several histological subtypes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback